US 11,701,413 B2
RNA for treatment of autoimmune diseases
Ugur Sahin, Mainz (DE); Sebastian Kreiter, Mainz (DE); Christina Krienke, Dienheim (DE); Jutta Petschenka, Mainz (DE); Lena Mareen Kranz, Mainz (DE); and Mustafa Diken, Mainz (DE)
Assigned to BioNTech SE, Mainz (DE); and TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH, Mainz (DE)
Appl. No. 16/500,005
Filed by BioNTech SE, Mainz (DE); and TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH, Mainz (DE)
PCT Filed Apr. 10, 2018, PCT No. PCT/EP2018/059188
§ 371(c)(1), (2) Date Oct. 1, 2019,
PCT Pub. No. WO2018/189193, PCT Pub. Date Oct. 18, 2018.
Claims priority of application No. PCT/EP2017/058651 (WO), filed on Apr. 11, 2017.
Prior Publication US 2020/0061166 A1, Feb. 27, 2020
Int. Cl. A61K 39/00 (2006.01); A61P 37/06 (2006.01); C12N 15/11 (2006.01); C12N 15/117 (2010.01)
CPC A61K 39/0008 (2013.01) [A61P 37/06 (2018.01); C12N 15/11 (2013.01); C12N 15/117 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55555 (2013.01); C12N 2310/335 (2013.01)] 8 Claims
 
1. A method of treating an autoimmune disease in a subject,
comprising administering to the subject a composition comprising a non-immunogenic RNA encoding a peptide or polypeptide comprising an autoantigen or a fragment thereof, or a variant of the autoantigen or fragment, wherein the non-immunogenic RNA comprises 1-methyl-pseudouridine, wherein the non-immunogenic RNA is formulated in a F12 liposome, and wherein the composition does not comprise dsRNA.